Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 02, 2024 06:00 ET
|
Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
Smart Immune appoints key new members to its Board of Directors
February 16, 2024 02:00 ET
|
Smart Immune
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell...
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
December 04, 2023 06:46 ET
|
Smart Immune
Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage...
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform
November 10, 2023 05:52 ET
|
Smart Immune
Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform Clinical-stage T-cell progenitor therapy aims to re-arm the immune system against cancer and infection New class of...
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023
November 02, 2023 09:00 ET
|
Smart Immune
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
May 11, 2023 11:58 ET
|
Smart Immune
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
January 23, 2023 07:01 ET
|
Consilium Strategic Communications
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to...
Smart Immune appoints world-class Clinical Advisory Board
November 21, 2022 07:00 ET
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
September 13, 2022 07:00 ET
|
Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...